Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Project details
Japanese biopharmaceutical start-up seeks about USD 10 million B-round financing
| Project region | Japan |
|---|---|
| Industry | Pharmeceuticals & Chemical |
| Total value of the target | N/A |
| Expected target net rate of return after deducting all taxes and fees | N/A |
| Validity period of pending order | 365 |
CONTACT ADVISOR
Simon Laube
Senior Associate, International Business Advisory
| Project highlights | DNA & RNA editing - technology licencing |
|---|---|
| Project description |
The Japanese company develops DNA and RNA editing technology in the field of innovative medicines and chemical medicines, whose intellectual property assets may be granted rights to others under a licence, sublicence or other contract. The company's core is RNA-PPR technology. Its current products include repetitive motif RNA control platform, RNA splicing control platform and protein translation activation platform. The company seeks about USD 10 million (JPY 13 billion) B-round financing. |
Enquire for more information about our services, and how we can help solve challenges for your organization
Contact Us